Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Hybridoma Technology01:31

Hybridoma Technology

18.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.8K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and characterization of monoclonal antibodies to spring viraemia of carp virus.

Veterinary immunology and immunopathology·2008
Same author

Electrophysiological characterization of a novel Kv channel blocker N,N'-[oxybis(2,1-ethanediyloxy-2,1-ethanediyl) ]bis(4-methyl)-benzenesulfonamide found in virtual screening.

Acta pharmacologica Sinica·2008
Same author

Cloning and characterization of an rRNA methyltransferase from Sorangium cellulosum.

Biochemical and biophysical research communications·2008
Same author

Reconstruction of anophthalmic orbits and contracted eye sockets with microvascular radial forearm free flaps.

Ophthalmic plastic and reconstructive surgery·2008
Same author

Using low intensity ultrasound to improve the efficiency of biological phosphorus removal.

Ultrasonics sonochemistry·2008
Same author

[Study on the spectrum of the flocculent conformation of polymer ferric sulfate flocculants].

Guang pu xue yu guang pu fen xi = Guang pu·2008

Related Experiment Video

Updated: Apr 20, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Multiple myeloma.

Sarah A Holstein1, Hong Liu1, Philip L McCarthy1

  • 1Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

Hematology/Oncology Clinics of North America
|December 3, 2014
PubMed
Summary
This summary is machine-generated.

Autologous stem cell transplant (ASCT) is key for myeloma treatment. Future profiling will refine ASCT timing and identify patients benefiting from allogeneic stem cell transplant.

Keywords:
Immunomodulatory agentsMaintenance therapyProteasome inhibitorsReduced-intensity conditioning

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Experiment Videos

Last Updated: Apr 20, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Autologous stem cell transplant (ASCT) is a cornerstone in multiple myeloma management.
  • The precise indications for allogeneic stem cell transplant in myeloma are still under investigation.
  • Emerging data highlight the importance of post-transplant maintenance strategies.

Purpose of the Study:

  • To review the current role and future directions of stem cell transplantation in multiple myeloma.
  • To discuss the evolving landscape of allogeneic stem cell transplant.
  • To emphasize the impact of maintenance therapy on patient outcomes.

Main Methods:

  • Review of current literature and clinical evidence regarding stem cell transplantation in multiple myeloma.
  • Analysis of the predictive value of emerging diagnostic techniques.
  • Discussion of treatment stratification based on patient subgroups.

Main Results:

  • ASCT is an established treatment for multiple myeloma.
  • Post-transplant maintenance therapy demonstrates significant improvements in outcomes.
  • Cytogenetic and gene expression profiling are expected to enhance patient stratification.

Conclusions:

  • ASCT remains central to myeloma therapy, with its optimal timing potentially refined by future diagnostics.
  • Allogeneic stem cell transplant's role is evolving and requires further definition.
  • Personalized treatment strategies, informed by advanced profiling, will optimize stem cell transplant selection and timing for myeloma patients.